San Diego, June 22, 2025 – ProSciento, Inc., a clinical research organization (CRO) focused on metabolic diseases, presented two scientific posters at the American Diabetes Association (ADA) 85th Scientific Sessions, taking place June 20–23, 2025, in Chicago. Recognized as one of the most influential global events in diabetes research, the ADA Scientific Sessions convene leading clinicians, scientists, and industry innovators to share groundbreaking discoveries and advancements in diabetes care.
Poster: 1898-LB – Amplifying the Patient Voice—Understanding Motivations and Barriers in Type 2 Diabetes Clinical Trial Participation
- Presented: Sunday, June 22, 12:30 – 1:30 PM (Central), Poster Hall F1
This study surveyed individuals with type 2 diabetes to assess factors influencing clinical trial participation, and the findings offer critical insights that can help refine patient recruitment strategies and improve diversity and retention in clinical trials.
Link to abstract: https://diabetesjournals.org/diabetes/article/74/Supplement_1/1898-LB/159225/1898-LB-Amplifying-the-Patient-Voice-Understanding
Poster: 1980-LB – Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist: Results from a Phase 1 Study
- Presented: Sunday, June 22, 12:30 – 1:30 PM (Central), Poster Hall F1
This first-in-human trial evaluated HM15275 in both healthy and obese adults, providing key insights into its safety profile and pharmacokinetics.
Link to the abstract: https://diabetesjournals.org/diabetes/article/74/Supplement_1/1980-LB/159987/1980-LB-Safety-Tolerability-and-Pharmacokinetics
About ProSciento
ProSciento is the leading provider of clinical research and patient engagement solutions for metabolic continuum diseases with unparalleled expertise in diabetes, obesity, and steatotic liver disease. As a full-service clinical research organization (CRO), ProSciento works with clients of all sizes worldwide to design and conduct multinational clinical trials, from early clinical development planning through phase III. With two decades as a leading scientific contributor to metabolic continuum research, ProSciento has trusted relationships with clients, partners, and patients, supporting the development of therapeutics and devices that make an important difference in the lives of individuals with metabolic diseases. For more information, please visit www.prosciento.com.